IP Library Granted Patent US 7,060,847
Granted Patent B2
US 7,060,847 · App. 10/622,254 · Granted Jun 13, 2006

Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,060,847
App. No.
10/622,254
Granted
Jun 13, 2006
Kind
B2
Abstract

The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.

Claims (11)

1. A compound having the structure

where L is CO or CH 2 , X is NH or O, M is a saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted, straight or branched chain of 1-10 carbon atoms, Y is an activated functionality selected from the group consisting of active esters, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups, and aldehydes, and R 1 is H, CH 3 , C 2 H 5 , or C 3 H 7 , R 2 is CH 3 or C 2 H 5 , and R 3 is a protecting group or H.

2. The compound of claim 1 wherein X is NH, Y is an activated ester, R 1 is CH 3 , R 2 is CH 3 , and R 3 is a protecting group. [MDMA activated hapten]

3. The compound of claim 1 wherein X is NH, Y is an activated ester, R 1 is C 2 H 5 , R 2 is CH 3 , and R 3 is a protecting group. [MDEA activated hapten]

4. The compound of claim 1 wherein X is NH, Y is an activated ester, R 1 is H, R 2 is CH 3 , and R 3 is a protecting group. [MDA activated hapten]

5. A compound having the structure

where L is CO or CH 2 , X is NH or O, M is a saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted, straight or branched chain of 1-10 carbon atoms, Z is a carrier molecule, R 1 is H, CH 3 , C 2 H 5 , or C 3 H 7 , and R 2 is CH 3 or C 2 H 5 .

6. The compound of claim 5 wherein X is NH, Z is selected from the group consisting of KLH, BSA, and aminodextran, R 1 is H, CH 3 , or C 2 H 5 , and R 2 is CH 3 or C 2 H 5 .

7. An antibody generated in response to a compound having the structure

where L is CO or CH 2 , X is NH or O, M is a saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted, straight or branched chain of 1-10 carbon atoms, Z is a carrier molecule selected from the group consisting of proteins, polypeptides, and polysaccharides, R 1 is H, CH 3 , C 2 H 5 , or C 3 H 7 , and R 2 is CH 3 or C 2 H 5 .

8. The antibody of claim 7 wherein L is CH 2 , X is NH, M is OC(CH 2 ) 2 CO, Z is KLH, R 1 is CH 3 or C 2 H 5 , and R 2 is CH 3 . [This covers immunogens 1P (R 1 ═CH 3 ) and 2U (R 1 ═C 2 H 5 ), which gave rise to the claimed mabs.]

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2004
From: ROCHE DIAGNOSTICS CORPORATION
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 015201/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: GHOSHAL, MITALI; SIGLER, GERALD F.; ROOT, RICHARD TERRY; OUYANG, ANLONGA; SALAMONE, SALVATORE J.
To: ROCHE DIAGNOSTICS CORPORATION
Reel/Frame 014793/0915 →